ALX Oncology Holdings Inc. (ALXO) DCF Valuation

ALX Oncology Holdings Inc. (ALXO) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

ALX Oncology Holdings Inc. (ALXO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Enhance your investment strategies with the ALXO DCF Calculator! Explore authentic ALX Oncology financials, adjust growth projections and expenses, and instantly observe how these modifications affect ALXO's intrinsic value.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 4.8 1.2 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -75.35 -100 0 0 -43.84 -43.84 -43.84 -43.84 -43.84
EBITDA -18.8 -43.5 -83.5 -122.0 -158.4 .0 .0 .0 .0 .0
EBITDA, % -391.14 -3676.9 100 100 100 20 20 20 20 20
Depreciation .4 .2 .7 1.5 .8 .0 .0 .0 .0 .0
Depreciation, % 8.94 17.09 100 100 100 65.21 65.21 65.21 65.21 65.21
EBIT -19.2 -43.7 -84.2 -123.4 -159.2 .0 .0 .0 .0 .0
EBIT, % -400.08 -3693.99 100 100 100 20 20 20 20 20
Total Cash 9.0 434.2 363.7 282.9 182.7 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .5 .0 .0 .0 .0
Account Receivables, % 11.18 0 100 100 100
Inventories .0 .0 .0 -17.7 .0 .0 .0 .0 .0 .0
Inventories, % 0 0 100 100 100 60 60 60 60 60
Accounts Payable 3.7 .0 3.8 8.1 8.6 .0 .0 .0 .0 .0
Accounts Payable, % 78.15 0.33841 100 100 100 75.7 75.7 75.7 75.7 75.7
Capital Expenditure -.4 .0 -4.9 -1.4 -1.3 .0 .0 .0 .0 .0
Capital Expenditure, % -7.36 -2.62 100 100 100 -2 -2 -2 -2 -2
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -19.2 -43.9 -84.2 -123.5 -159.2 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -15.9 -46.9 -84.6 -101.4 -176.9 -8.6 .0 .0 .0 .0
WACC, % 9.29 9.29 9.29 9.29 9.29 9.29 9.29 9.29 9.29 9.29
PV UFCF
SUM PV UFCF -7.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -8
Net Debt -5
Equity Value -3
Diluted Shares Outstanding, MM 43
Equity Value Per Share -0.06

What You Will Get

  • Real ALXO Financial Data: Pre-filled with ALX Oncology's historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See ALX Oncology's intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive ALXO Data: Pre-filled with ALX Oncology Holdings Inc.'s historical financials and future projections.
  • Fully Customizable Inputs: Modify revenue growth, profit margins, discount rates, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on your parameters.
  • Scenario Testing: Develop multiple forecasting scenarios to evaluate various valuation results.
  • User-Friendly Interface: Intuitive, organized, and crafted for both professionals and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review ALX Oncology Holdings Inc.'s (ALXO) pre-filled financial data and forecasts.
  3. Step 3: Modify critical inputs such as revenue growth, WACC, and tax rates (highlighted cells).
  4. Step 4: Observe the DCF model update in real-time as you adjust assumptions.
  5. Step 5: Analyze the outputs and utilize the results for your investment decisions.

Why Choose ALX Oncology Holdings Inc. (ALXO)?

  • Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs in oncology.
  • Strong Research Foundation: Backed by robust clinical data and a team of experienced professionals.
  • Commitment to Patients: Focused on improving patient outcomes through targeted treatments.
  • Collaborative Approach: Partnerships with leading institutions to enhance research and development.
  • Industry Recognition: A trusted name in oncology, known for excellence and integrity in the field.

Who Should Use ALX Oncology Holdings Inc. (ALXO)?

  • Investors: Gain insights into the biotech sector with a reliable analysis tool tailored for ALX Oncology Holdings Inc. (ALXO).
  • Financial Analysts: Streamline your research with a comprehensive model designed for evaluating ALX Oncology Holdings Inc. (ALXO).
  • Consultants: Effortlessly modify the framework for client discussions or strategic presentations related to ALX Oncology Holdings Inc. (ALXO).
  • Biotech Enthusiasts: Enhance your knowledge of oncology investments through detailed case studies on ALX Oncology Holdings Inc. (ALXO).
  • Educators and Students: Utilize it as a hands-on resource in courses focused on biotechnology and investment strategies.

What the Template Contains

  • Historical Data: Includes ALX Oncology Holdings Inc.'s (ALXO) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate ALX Oncology's (ALXO) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of ALX Oncology Holdings Inc.'s (ALXO) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.